Nkarta Inc (NKTX) Stock Price, Quote & News

Company Profile

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for...

Industry: Biotechnology

Sector: Healthcare

Phone: 925 407 1049

Website: www.nkartatx.com

Address:

1150 Veterans Boulevard, South San Francisco, United States

Synkum Oct. 4 at 1:33 AM

$NKTX Paul Hastings: “I'm headed to Boston next Wednesday, Oct. 8, for the Fierce Biotech Summit, where I'll be doing a fireside chat focused on the promise of cell therapy to treat autoimmune disease. This mission matters to me deeply as a CEO and as a patient who has been living with an autoimmune disease since the age of 13. The scientific progress we're making in this area is exhilarating. There's now a valid reason to hope that innovators can finally deliver a solution that stops the immune system from turning on itself.”

0 · Reply

Lukey63 Oct. 3 at 4:50 PM

$NKTX In a sea of green there is this….turd. Despite a really solid BS and long runway. Maybe next week.

0 · Reply

Joesh82 Oct. 2 at 1:13 PM

$NKTX Looking at the 50 week sma chart, there is a clear trendline that the price has struggled with, with it now being at 2.14 it shouldn't be too difficult to close above this and give us a bigger move up.

0 · Reply

purplesniper Sep. 30 at 1:39 PM

$NKTX

0 · Reply

youbi336 Sep. 25 at 5:58 PM

$NKTX Kyverna went back to $6.X and this is still dead after the attempt on the 200 EMA. WTH is wrong with this stock?

0 · Reply

Paulfrench Sep. 23 at 5:33 AM

Hello $NKTX Very nice candle yesterday that crosses the 200MA effortlessly. It's a powerful signal for upward continuation.

0 · Reply

purplesniper Sep. 23 at 3:45 AM

$NKTX by mid-next year I’m hoping this is 3.50+

0 · Reply

vu_jade Sep. 22 at 3:44 PM

$NKTX looking better

0 · Reply

pleiades108 Sep. 22 at 3:25 PM

$NKTX Closed scalp. Looking for the lows to be taken out again in the ongoing correction. Bullish long-term though.

0 · Reply

pleiades108 Sep. 18 at 9:07 AM

$NKTX This bio stock reminds me of OCGN, TA wise. With patience, you will enjoy the fruits. OCGN is currently in launch phase, if it hasn't already as an example.

0 · Reply

Nkarta to Participate in a September Investor Conference

Aug 12, 2025, 4:01 PM EDT - 7 weeks ago

Nkarta Reports Second Quarter 2025 Financial Results and Corporate Highlights

Jul 23, 2025, 8:01 AM EDT - 2 months ago

Nkarta to Participate in the H.C. Wainwright “HCW@Home” Series

Jul 22, 2025, 12:40 AM EDT - 2 months ago

Nkarta: Holding Its Support Steady Ahead Of First Data Readouts In 2025

Jun 6, 2025, 8:52 AM EDT - 4 months ago

Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune Focus

May 15, 2025, 3:46 PM EDT - 5 months ago

Nkarta Downgraded, Analyst Cites Competitive Pressure In Autoimmune Space

May 14, 2025, 4:01 PM EDT - 5 months ago

Nkarta Reports First Quarter 2025 Financial Results and Corporate Highlights

Apr 1, 2025, 8:01 AM EDT - 6 months ago

Nkarta to Participate in an April Investor Conference

Mar 31, 2025, 10:41 AM EDT - 6 months ago

Nkarta: Grinding Lower, Trying To Find Support

Mar 31, 2025, 10:15 AM EDT - 6 months ago

Nkarta: Betting On The Turnaround

Mar 27, 2025, 12:50 PM EDT - 6 months ago

Why Is Autoimmune Disease Focused Nkarta Stock Trading Higher On Thursday?

Mar 26, 2025, 4:01 PM EDT - 6 months ago

Nkarta Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights

Feb 25, 2025, 8:01 AM EST - 7 months ago

Nkarta to Participate in March Investor Conferences

Dec 5, 2024, 6:01 AM EST - 10 months ago

Nkarta Announces IND Clearance of Investigator-Sponsored Trial in Myasthenia Gravis and Opening of Enrollment for Ntrust-2

Nov 26, 2024, 7:02 AM EST - 11 months ago

Nkarta to Participate in an Upcoming Investor Conference

Nov 7, 2024, 4:02 PM EST - 11 months ago

Nkarta Reports Third Quarter 2024 Financial Results and Corporate Highlights

Oct 8, 2024, 9:07 AM EDT - 1 year ago

Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month

AMN MRNA

Sep 3, 2024, 4:01 PM EDT - 1 year ago

Nkarta to Participate in Upcoming Investor Conference

Aug 14, 2024, 3:08 PM EDT - 1 year ago

Nkarta: NK Cell Therapy Biotech With Good Standing Targeting R/R NHL Patients

Aug 13, 2024, 9:03 PM EDT - 1 year ago

Correction: Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights

Aug 13, 2024, 4:01 PM EDT - 1 year ago

Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights

Jul 24, 2024, 6:00 AM EDT - 1 year ago

Nkarta Announces Initiation of Investigator-Sponsored Clinical Trial Evaluating NKX019 for Systemic Lupus Erythematosus

Jul 16, 2024, 6:01 AM EDT - 1 year ago

Nkarta Announces Leadership Updates, Appoints Nadir Mahmood as President

Jun 27, 2024, 6:00 AM EDT - 1 year ago

Nkarta Initiates Clinical Trial of NKX019 in Lupus Nephritis with First Patient in Screening and Announces Pipeline Expansion to Additional Autoimmune Indications

Jun 13, 2024, 4:01 PM EDT - 1 year ago

Nkarta Adds Experienced Leader in Autoimmune R&D, George Vratsanos, M.D., FACR, to Board of Directors

May 25, 2024, 2:20 AM EDT - 1 year ago

Nkarta: Finally An Attractive Valuation

May 9, 2024, 4:01 PM EDT - 1 year ago

Nkarta Reports First Quarter 2024 Financial Results and Corporate Highlights

Apr 27, 2024, 10:27 AM EDT - 1 year ago

Nkarta: Down 50% Since March With A Clinical Catalyst Ahead

Apr 8, 2024, 12:55 PM EDT - 1 year ago

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors

Apr 5, 2024, 3:35 PM EDT - 1 year ago

The Law Offices of Frank R. Cruz Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors

Apr 3, 2024, 4:02 PM EDT - 1 year ago

Nkarta to Participate in Upcoming Investor Conferences

Mar 25, 2024, 4:03 PM EDT - 1 year ago

Nkarta: NK Cell Therapy Advancement On Two Fronts

Mar 25, 2024, 6:30 AM EDT - 1 year ago

Nkarta Announces Pricing of $240 Million Underwritten Offering

Mar 21, 2024, 4:01 PM EDT - 1 year ago

Nkarta Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights

Mar 13, 2024, 1:22 PM EDT - 1 year ago

Nkarta's Strategic Advances In Cell Therapy For Autoimmune Disorders

Jan 25, 2024, 12:12 PM EST - 1 year ago

Nkarta: Possible Upside From H1 Update, If Positive

Dec 9, 2023, 8:31 PM EST - 1 year ago

Nkarta Presents NKX101 Clinical Data at the 2023 American Society of Hematology Annual Meeting & Exposition

Nov 9, 2023, 4:02 PM EST - 2 years ago

Nkarta Reports Third Quarter 2023 Financial Results and Corporate Highlights

Nov 7, 2023, 8:02 AM EST - 2 years ago

Nkarta to Participate at Upcoming Investor Conferences

Oct 17, 2023, 11:47 AM EDT - 2 years ago

Lupus Therapeutics Announces Partnership to Support the Evaluation of Natural Killer (NK) Cell Therapy in Lupus Nephritis

Oct 17, 2023, 7:01 AM EDT - 2 years ago

Nkarta Receives FDA Clearance of IND Application for NKX019 in Lupus Nephritis

Oct 16, 2023, 4:01 PM EDT - 2 years ago

Nkarta to Host Conference Call on Tuesday, October 17 at 8am ET to Discuss Expansion of Clinical Pipeline and Organizational Cost Measures

Aug 10, 2023, 7:01 AM EDT - 2 years ago

Nkarta Reports Second Quarter 2023 Financial Results and Corporate Highlights

Aug 3, 2023, 8:02 AM EDT - 2 years ago

Nkarta to Participate at Upcoming Investor Conference

Jul 5, 2023, 4:02 PM EDT - 2 years ago

Nkarta Appoints Alyssa Levin Chief Financial and Business Officer

$Nkarta Updates Clinical Progress of CAR-NK Cell Therapy NKX101 for Patients with Relapsed or Refractory Acute Myeloid Leukemia$

Jun 27, 2023, 7:01 AM EDT - 2 years ago

Nkarta Updates Clinical Progress of CAR-NK Cell Therapy NKX101 for Patients with Relapsed or Refractory Acute Myeloid Leukemia

Jun 26, 2023, 4:01 PM EDT - 2 years ago

Nkarta to Host Conference Call to Discuss Updated Clinical Data from NKX101 NK Cell Therapy Program

Jun 10, 2023, 10:47 AM EDT - 2 years ago

Nkarta Presents NKX019 Clinical Data at the European Hematology Association 2023 Congress and 17th International Conference on Malignant Lymphoma

May 11, 2023, 4:02 PM EDT - 2 years ago

Nkarta Reports First Quarter 2023 Financial Results and Corporate Highlights

Synkum Oct. 4 at 1:33 AM

0 · Reply

Lukey63 Oct. 3 at 4:50 PM

$NKTX In a sea of green there is this….turd. Despite a really solid BS and long runway. Maybe next week.

0 · Reply

Joesh82 Oct. 2 at 1:13 PM

0 · Reply

purplesniper Sep. 30 at 1:39 PM

$NKTX

0 · Reply

youbi336 Sep. 25 at 5:58 PM

$NKTX Kyverna went back to $6.X and this is still dead after the attempt on the 200 EMA. WTH is wrong with this stock?

0 · Reply

Paulfrench Sep. 23 at 5:33 AM

Hello $NKTX Very nice candle yesterday that crosses the 200MA effortlessly. It's a powerful signal for upward continuation.

0 · Reply

purplesniper Sep. 23 at 3:45 AM

$NKTX by mid-next year I’m hoping this is 3.50+

0 · Reply

vu_jade Sep. 22 at 3:44 PM

$NKTX looking better

0 · Reply

pleiades108 Sep. 22 at 3:25 PM

$NKTX Closed scalp. Looking for the lows to be taken out again in the ongoing correction. Bullish long-term though.

0 · Reply

pleiades108 Sep. 18 at 9:07 AM

$NKTX This bio stock reminds me of OCGN, TA wise. With patience, you will enjoy the fruits. OCGN is currently in launch phase, if it hasn't already as an example.

0 · Reply

pleiades108 Sep. 17 at 11:57 AM

$NKTX Correction still ongoing, but when finished, hopefully going into October, it will have its day!

0 · Reply

highnihilism Sep. 17 at 10:19 AM

IWM: Russell 2000 → $NABL N-Able $NKTX Nkarta $OEC Orion $TZOO Travelzoo $IART Integra Lifesciences

0 · Reply

MMM_invest Sep. 16 at 10:08 PM

$NKTX Cash balance of $334.0 million on June 30, 2025, including cash, cash equivalents, and investments, expected to fund operations into 2029

0 · Reply

None_ Sep. 16 at 12:42 AM

$FATE $IPSC $NKTX Found this https://investorshub.advfn.com/boards/read_msg.aspx?message_id=176698547

0 · Reply

youbi336 Sep. 15 at 1:54 PM

$NKTX Still hurt from the attempt on the 200 EMA. It will sweep for liquidity in the 1.9x range and try again most likely. Hopefully, it will break it next time.

0 · Reply

Lukey63 Sep. 13 at 5:07 AM

$NKTX This stock is killing me. I have 30 Stocks up significantly and this one turd. 🤣

0 · Reply

Arcides Sep. 12 at 4:37 PM

$NKTX another sample that breakouts rarely works on this market...makes a breakout on 3X average volume on aug 13 and is gone.

0 · Reply

Lukey63 Sep. 12 at 1:37 PM

$NKTX GMAFB. Liquidate and give us our $4+ cash

0 · Reply

hopeteen Sep. 12 at 8:20 AM

$NKTX I’ll wait for 1.90 for a new entry.

0 · Reply

vu_jade Sep. 10 at 4:33 PM

$NKTX don’t force me to buy more

1 · Reply

vu_jade Sep. 9 at 9:25 PM

$NKTX smelling news coming! We are ready!

0 · Reply

vu_jade Sep. 9 at 6:10 PM

$NKTX fell like an announcement will be coming soon .. see you at $4

1 · Reply

Market Cap	151.28M
Revenue (ttm)	0.00
Net Income (ttm)	-108.79M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	733,000
Avg Vol	585,398
Day's Range	N/A - N/A
Shares Out	71.03M
Stochastic %K	63%
Beta	0.86
Analysts	Strong Sell
Price Target	$12.40